ZA988920B - Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome - Google Patents

Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome

Info

Publication number
ZA988920B
ZA988920B ZA988920A ZA988920A ZA988920B ZA 988920 B ZA988920 B ZA 988920B ZA 988920 A ZA988920 A ZA 988920A ZA 988920 A ZA988920 A ZA 988920A ZA 988920 B ZA988920 B ZA 988920B
Authority
ZA
South Africa
Prior art keywords
treatment
pharmaceutical composition
inflammatory bowel
bowel disease
bowel syndrome
Prior art date
Application number
ZA988920A
Inventor
John Rhodes
Brian Kenneth Evans
Original Assignee
John Rhodes
Brian Kenneth Evans
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by John Rhodes, Brian Kenneth Evans filed Critical John Rhodes
Publication of ZA988920B publication Critical patent/ZA988920B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA988920A 1997-09-30 1998-09-30 Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome ZA988920B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9720797.1A GB9720797D0 (en) 1997-09-30 1997-09-30 Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome

Publications (1)

Publication Number Publication Date
ZA988920B true ZA988920B (en) 1999-06-09

Family

ID=10819864

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA988920A ZA988920B (en) 1997-09-30 1998-09-30 Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome

Country Status (7)

Country Link
EP (1) EP1019038A1 (en)
JP (1) JP2001517697A (en)
AU (1) AU9273198A (en)
CA (1) CA2304516A1 (en)
GB (1) GB9720797D0 (en)
WO (1) WO1999016436A1 (en)
ZA (1) ZA988920B (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003513045A (en) * 1999-11-01 2003-04-08 ロデバ・リミテッド Composition for treating and treating constipation and irritable bowel syndrome
US7081475B2 (en) 2001-09-14 2006-07-25 Prolx Pharmaceuticals Corp. Wortmannin analogs and methods of using same
EP1690557A1 (en) * 2005-02-11 2006-08-16 NOLabs AB Device for treatment of rectal disorders, and manufacturing process for the same
WO2006084913A2 (en) * 2005-02-11 2006-08-17 Nolabs Ab Device for treatment of rectal disorders, and manufacturing process for the same, involving nitric oxide
US20070135380A1 (en) 2005-08-12 2007-06-14 Radiorx, Inc. O-nitro compounds, pharmaceutical compositions thereof and uses thereof
US7507842B2 (en) 2005-08-12 2009-03-24 Radiorx, Inc. Cyclic nitro compounds, pharmaceutical compositions thereof and uses thereof
AU2012203798B2 (en) * 2005-08-12 2013-11-07 Northrop Grumman Systems Corporation O-nitro compounds, pharmaceutical compositons thereof and uses thereof
EP1941876A1 (en) * 2006-12-28 2008-07-09 Lacer, S.A. Isosorbide mononitrate derivatives for the treatment of Inflammation and ocular hypertension
US8471041B2 (en) 2010-02-09 2013-06-25 Alliant Techsystems Inc. Methods of synthesizing and isolating N-(bromoacetyl)-3,3-dinitroazetidine and a composition including the same
US8664247B2 (en) 2011-08-26 2014-03-04 Radiorx, Inc. Acyclic organonitro compounds for use in treating cancer
WO2013052803A2 (en) 2011-10-07 2013-04-11 Radiorx, Inc. Methods and compositions comprising a nitrite-reductase promoter for treatment of medical disorders and preservation of blood products
JP6019126B2 (en) 2011-10-07 2016-11-02 エピセントアーレックス・インコーポレイテッドＥｐｉｃｅｎｔＲｘ， Ｉｎｃ． Organic nitrothioether compounds and their medical applications
US10342778B1 (en) 2015-10-20 2019-07-09 Epicentrx, Inc. Treatment of brain metastases using organonitro compound combination therapy
US9987270B1 (en) 2015-10-29 2018-06-05 Epicentrix, Inc. Treatment of gliomas using organonitro compound combination therapy
KR20190040931A (en) 2016-01-11 2019-04-19 에피센트알엑스, 인코포레이티드 Compositions and methods for intravenous administration of 2-bromo-1- (3,3-dinitroazetidin-1-yl) ethanone
WO2017137489A1 (en) * 2016-02-12 2017-08-17 Dsm Ip Assets B.V. Anti-methanogenic compositions and uses thereof
EP3526195A4 (en) 2016-10-14 2020-05-20 EpicentRx, Inc. Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine
US11744859B2 (en) 2017-07-07 2023-09-05 Epicentrx, Inc. Compositions and methods for parenteral administration of therapeutic agents
WO2019164593A2 (en) 2018-01-08 2019-08-29 Epicentrx, Inc. Methods and compositions utilizing rrx-001 combination therapy for radioprotection
CN110200921B (en) * 2019-06-19 2020-11-17 华中科技大学 Anti-inflammatory liposome with targeting effect and preparation and application thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4428925A (en) * 1981-12-18 1984-01-31 Key Pharmaceuticals, Inc. Sustained release glycerol trinitrate
DE3728563A1 (en) * 1987-08-27 1989-03-09 Pohl Boskamp Gmbh Chem Pharma MEDICINAL PRODUCT CONTAINING N-ALKYLSCOPOLAMININE SALT AND NITROGLYCERIN, METHOD FOR THE PRODUCTION AND USE THEREOF
US5004601A (en) * 1988-10-14 1991-04-02 Zetachron, Inc. Low-melting moldable pharmaceutical excipient and dosage forms prepared therewith
AU3237193A (en) * 1991-12-11 1993-07-19 Brigham And Women's Hospital S-nitrosothiols as smooth muscle relaxants and therapeutic uses thereof
US5632981A (en) * 1992-08-24 1997-05-27 The United States Of America As Represented By The Department Of Health And Human Services Biopolymer-bound nitric oxide-releasing compositions, pharmaceutical compositions incorporating same and methods of treating biological disorders using same
SK281042B6 (en) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Sustained-release hydrogel preparation
JPH06227969A (en) * 1993-02-02 1994-08-16 Masayasu Sugihara Method for improving enteric property of medicine and medicine composition obtained thereby
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
DE4420523A1 (en) * 1994-06-13 1995-12-14 Cassella Ag Treating and preventing SIRS, e.g. in shock, arthritis or peritonitis
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system

Also Published As

Publication number Publication date
GB9720797D0 (en) 1997-12-03
EP1019038A1 (en) 2000-07-19
AU9273198A (en) 1999-04-23
WO1999016436A1 (en) 1999-04-08
JP2001517697A (en) 2001-10-09
CA2304516A1 (en) 1999-04-08

Similar Documents

Publication Publication Date Title
GB9720797D0 (en) Pharmaceutical composition for the treatment of inflammatory bowel disease and irritable bowel syndrome
HUP0103147A3 (en) Pharmaceutical composition comprising glp1 and their use for the treatment of functional dyspepsia and/or irritable bowel syndrome
IL132145A (en) Compositions for treating inflammatory bowel disease and uses thereof
HK1022835A1 (en) Pharmaceutical composition for treatment of diabetes
ZA987800B (en) Pharmaceutical composition of meloxicam
IL117417A (en) Pharmaceutical composition comprising rapamycin for treating cardiac inflammatory disease and its preparation
IL133420A0 (en) Pharmaceutical composition for combination of piperidinoalkanol-decongestant
AU2124397A (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
IL125735A0 (en) Pharmaceutical compositions for the treatment of glaucoma
ID18663A (en) COMPOSITION OF PHARMACEUTICAL PLATED PHARMACEUTICALS
AUPO727097A0 (en) Method of treatment of hepatoma and pharmaceutical compositions for use therein
HUP0003851A3 (en) Pharmaceutical composition for the treatment or prevention of glomerulopathy
AU2027595A (en) Pharmaceutical composition for treating inflammatory bowel diseases
GB2311940B (en) Pharmaceutical compositions for the treatment of rhinitis
HUP0002346A3 (en) Pharmaceutical composition for the treatment of mental illness in mammals
HUP0003244A2 (en) Novel triptolide derivatives useful in the treatment of autoimmune diseases and pharmaceutical compositions thereof
IL121096A0 (en) Pharmaceutical compositions for the treatment of liver disease
HUP0000460A3 (en) Imidazopyridazines and pharmaceutical compositions thereof
AU6786898A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU6786798A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU8580598A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
AU8049098A (en) Composition and methods for the treatment of inflammatory diseases
AU6786698A (en) Methods and compositions for the diagnosis and treatment of neuropsychiatric di sorders
HUP0000569A3 (en) Use of equilenin for producing pharmaceutical compositions for the treatment of free radical induced disease states